drugset / Trial / NCT04106219
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Phase 1
Active not recruiting
71 enrolled
Eli Lilly and Company
Innovative Therapies for Children with Cancer in Europe (ITCC) · collabNew Approaches to Neuroblastoma Therapy Consortium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Timeline
- Start
- 2020-06-11
- Primary completion
- 2022-04-13
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK-01 | Unknown | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Topotecan | Small molecule | — | Intravenous |